Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations.
OBJECTIVE
Up till now the role of simeprevir plasma concentrations has not been described in treated patients affected by chronic hepatitis C and with dermatological side-effects. In this study, we have evaluated a possible relationship between plasma levels and the onset of skin complaints for the first time.


METHODS
We report a clinical and pharmacokinetic analysis of 56 patients treated with simeprevir-based therapies.


RESULTS
Simeprevir plasma concentrations were significantly related to dermatological side-effects at early time-points (P<0.001). In logistic regression, simeprevir concentrations at 1 week was the best predictive factor forskin symptoms (OR=1.901, 95%IC: 1.001-2.304; P=0.007).


CONCLUSIONS
Simeprevir plasma measurements could be a useful tool in a real-life clinical setting for prevention of dermatological symptoms.
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy. Electronic address: lucio.boglione@unito.it.com.
Lucio
L
Boglione
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Amedeo
A
De Nicolò
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Simone
S
Mornese Pinna
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Jessica
J
Cusato
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Fabio
F
Favata
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Alessandra
A
Ariaudo
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Chiara
C
Carcieri
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Giuseppe
G
Cariti
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Giovanni
G
Di Perri
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Antonio
A
D'Avolio
D000328:Adult; D000998:Antiviral Agents / Q000097:blood / Q000493:pharmacokinetics; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D000069616:Simeprevir / Q000009:adverse effects* / Q000097:blood* / Q000493:pharmacokinetics; D012871:Skin Diseases / Q000139:chemically induced*; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin; D000069616:Simeprevir
Dermatological side-effects; HCV; Pharmacokinetics; Simeprevir; Therapeutic drug monitoring